NEW YORK (360Dx) – Atomo Diagnostics and Access Bio said today that they would leverage their rapid diagnostic testing technology as part of a collaboration that takes aim at expanding point-of-care HIV testing in global markets.
Atomo will supply its AtomoRapid lateral flow platform for use with an Access Bio rapid test that detects the presence of HIV antibodies in a single drop of blood obtained from a fingertip. The test result can be read in minutes, which is essential to enabling same-day diagnosis and early treatment, the firms said.
As part of the collaboration, Access Bio would commercialize a new test for use by medical professionals in clinical markets under its CareStart brand in territories across Africa, South East Asia, and South America, and in Commonwealth of Independent State countries.
Young Ho Choi, CEO and founder of Access Bio, said in a statement that Atomo’s all-in-one test devices simplify and standardize test procedures, and they "will help us improve the performance and user-friendliness of our HIV test for our customers."
He noted that the alliance with Atomo is "highly compatible" with the firm's established business channels, and that Access Bio is exploring other areas of collaboration to strengthen its portfolio in the mid-to-long term.
John Kelly, founder and CEO of Atomo, said that the partnership with Access Bio "adds significantly" to its long-term growth plans.
Financial and other terms of the deal were not disclosed.